Metabolic syndrome is a condition that individuals develop cardiovascular health, diabetes and others complicationsThe dramatic rise in the prevalence of obesity and type 2 diabetes mellitus (T2DM) is associated with increased mortality, morbidity as well as public health care expenses worldwide. The GLP1 is a class of incretins secreted by intestine that improve insulin secretion. The objective was evaluating the effect of treatment with Victoza® on cafeteria induced‐obese rats. The rats were divided in two groups: Control (animals that received chow diet) and DIET (animals that to 30th received cafeteria diet until 90th). Ten days before de experimental process the animals was divided in two groups again: CON GLP1 and DIET GLP1 (animals DIET that received subcutaneous injections of Victoza® 0,0077 mg/day during 10 days).The weight of fats are showed in table 1.
Fats
Normal Con
Normal Diet
Con GLP1
Diet GLP1
Retroperitoneal fat pad
8,01±0,93*
11,93±1,34
6,14±0,52
12,9±1,36
Periepidydimal fat pad
5,31±0,66*
10,92±1,16
4,66±0,50
10,46±1,36
mesenteric fat pad
4,06±0,46*†
9,64±1,42
2,64±0,33
6,21±1,0
The blood data showed that the cafeteria diet caused increased blood glucose levels, showed in figure 1.imageThe cafeteria diet also promoted increased triglycerides and treatment with Victoza® decreased in the Con GLP1 and Diet GLP1 groups being more significant in the diet group.imagePreliminary results showed treatment with Victoza® caused an increase in basal NO production of peritoneal macrophage for both control and diet groups, in opposites reduce the basal ROS production. In conclusion ours results showed that treatment of Victoza® causes reduction in glycemia and triglycerides and alters macrophages functions.These findings are of great importance since obesity is the major risk factor for several chronic diseases.
